Magnesium Supplementation for Sleep
(Mg-Form Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP or study-approved wearable data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.
Who Is on the Research Team?
Jeremy Swisher, MD
Principal Investigator
University of California, Los Angeles
Joshua Goldman, MD
Principal Investigator
University of California, Los Angeles
Are You a Good Fit for This Trial?
This trial is for UCLA varsity athletes who want to improve their sleep, recovery, and athletic performance. Participants should be healthy enough to take part in a supplement study and able to wear a fitness tracker at night.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Monitoring
Participants undergo baseline assessments and wearable monitoring
Treatment
Participants receive blinded nightly supplementation with magnesium glycinate, magnesium L-threonate, or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares two types of magnesium supplements (magnesium glycinate and magnesium L-threonate) with a placebo. Athletes are randomly assigned to one group, taking the supplement nightly for 4 weeks while their sleep and performance are monitored.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Participants randomized to this arm will take blinded magnesium L-threonate capsules nightly for 4 weeks. The current planning target is approximately 2 g/day total magnesium L-threonate, with elemental magnesium content, capsule count, and label language confirmed before activation.
Participants randomized to this arm will take blinded magnesium glycinate capsules nightly for 4 weeks. The current planning dose is approximately 240 mg elemental magnesium nightly, with final capsule count and label language based on the selected blinded formulation.
Participants randomized to this arm will take matching placebo capsules nightly for 4 weeks on the same blinded schedule.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.